ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ARQT Arcutis Biotherapeutics Inc

9.91
0.32 (3.34%)
After Hours
Last Updated: 09:00:07
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Arcutis Biotherapeutics Inc ARQT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.32 3.34% 9.91 09:00:07
Open Price Low Price High Price Close Price Previous Close
9.67 9.61 10.02 9.91 9.59
more quote information »

Recent News

Date Time Source Heading
28/3/202423:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
11/3/202423:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
11/3/202407:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
10/3/202408:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
07/3/202409:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202409:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202409:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202408:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
05/3/202409:47EDGAR2Form 144 - Report of proposed sale of securities
05/3/202409:42EDGAR2Form 144 - Report of proposed sale of securities
05/3/202409:40EDGAR2Form 144 - Report of proposed sale of securities
05/3/202408:10EDGAR2Form 8-K - Current report
05/3/202408:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
05/3/202400:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
02/3/202408:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/3/202408:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/3/202409:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
29/2/202415:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
29/2/202408:54EDGAR2Form 144 - Report of proposed sale of securities
29/2/202408:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/2/202408:10EDGAR2Form 8-K - Current report
29/2/202408:10GLOBEArcutis Announces Proposed Public Offering
29/2/202408:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
28/2/202408:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202423:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202423:44EDGAR2Form 8-K - Current report
27/2/202421:50GLOBEArcutis Announces Fourth Quarter and Full Year 2023..
17/2/202400:00GLOBEArcutis to Report Fourth Quarter and Full Year 2023..
16/2/202410:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202410:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202410:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202408:20EDGAR2Form 8-K - Current report
16/2/202408:19EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
14/2/202401:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202416:15EDGAR2Form EFFECT - Notice of Effectiveness
09/2/202408:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/2/202408:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/2/202409:22EDGAR2Form S-3 - Registration statement under Securities Act of..
01/2/202400:00GLOBEArcutis to Present at the Guggenheim Healthcare Talks – 6th..
30/1/202400:00GLOBEJournal of the American Academy of Dermatology Publishes..
25/1/202408:02EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
23/1/202400:00GLOBEZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment..
18/1/202408:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202408:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202408:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202408:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/1/202420:00GLOBEZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic..
12/1/202408:03EDGAR2Form SC TO-C - Written communication relating to an issuer..
12/1/202408:01EDGAR2Form 8-K - Current report
23/12/202309:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Your Recent History

Delayed Upgrade Clock